Article Published on Journal of Neuroinflammation Revealing Suciraslimab’s Dual Mechanism of Action in Combating Alzheimer’s Disease: Anti-Inflammation and Promotion of Amyloid-Beta Clearance

中國抗體製藥有限公司 SinoMab BioScience Limited (Incorporated in Hong Kong with limited liability) (Stock Code: 3681) Article Published on Journal of Neuroinflammation Revealing Suciraslimab’s Dual Mechanism of Action in Combating Alzheimer’s Disease: Anti-Inflammation and Promotion of Amyloid-Beta Clearance (11 February 2025 – Hong Kong) A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (“SinoMab” or the “Company”, Stock Code: 3681.HK), is pleased to announce that on 5 February 2025, a n article is published on the Journal of Neuroinflammation (Impact Factor 9.3), a top-ranking international journal on neuroscience and immunology. In the paper titled, “CD22 modulation alleviates amyloid β-induced neuroinflammation”, the authors reported data unveiling the dual mechanism of action of Suciraslimab, a c linical-stage anti -human CD22 antibody, in addressing Alzheimer ’s disease . The study demonstrates that Suciraslimab not only alleviates neuroinflammation but also promotes the clearance of amyloid -beta (A β), a hallmark of Alzheimer ’s pathology. This dual action positions Suciraslimab as a potential promising therapeutic candidate for neurodegenerative diseases, particularly Alzheimer’s disease. Neuroinflammation is a critical factor in the progression of neurodegenerative diseases, including Alzheimer’s disease, where plasma soluble CD22 (sCD22) levels are notably elevated in Alzheimer’s disease patients. This article reported that sCD22 promotes neuroinflammation both in vivo and in vitro. The study reveals that CD22 interacts with amyloid-beta (Aβ), and Suciraslimab enhances the internalization of the CD22-Aβ complex in microglia, the key immune cells responsible for regulating neuroinflammation and a major contributor to neurodegenerative processes. These findings underscore the significance of sCD22 in driving neuroinflammation and demonstrate the dual therapeutic potential of S uciraslimab by targeting CD22: mitigating A β-induced inflammation and enhancing Aβ phagocytosis. Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that, “SinoMab focuses on the development of innovative products through scientific excellence, with the goal of identifying differentiating products that address immunological diseases of unmet medical needs. We are encouraged by our findings that Suciraslimab has the therapeutic potential to revolutionize the treatment of Alzheimer’s disease by simultaneously addressing neuroinflammation and amyloid-β clearance and endorsed by being published on the renowned peer -reviewed journal Journal of Neuroinflammation. When further tapping into the potential of Suciraslimab, SinoMab is developing second generation anti -CD22 antibody parallely, which is potentially less immunogenic and with higher efficacy, according to our in -house in-vitro studies. The growing ageing population has led to a sharp rise in Alzheimer’s cases, posing a significant threat to the health and quality of life of the elderly. According to the report by Chen Zhu, the Vice Chairman of the Standing Committee of the 13th National People ’s Congress, the President of the Red Cross Society of China and the member of the Chinese Academy of Sciences, presented at the ‘2023 China Brain Health Conference’, there are 10 million Alzheimer's disease patients in China and the number is expected to continue growing. This study marks a significant milestone in the fight against Alzheimer’s disease, paving the way for innovative treatments that could improve the lives of millions of patients worldwide.” – END – About SinoMab BioScience Limited SinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. SinoMab is headquartered in Hong Kong with its R&D base in Hong Kong and production base in mainland China. The Company's flagship product Suciraslimab (SM03) is a potential global first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. SM03 (Suciraslimab) has completed the Phase III clinical tr ial for RA in China and is pending NMPA ’s marketing approval for RA in China. In addition, the Company possesses other potential first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthrit is (RA), Sjogren ’s syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases with major unmet clinical needs. About Journal of Neuroinflammation Journal of Neuroinflammation is an open access, peer-reviewed journal that focuses on interactions of the immune system (and especially the innate immune system) with the nervous system. This includes the roles of CNS immune mediators (such as microglia and astrocytes, and their expressed cytokines and chemokines) as well as the roles of peripheral neuro -immune interactions, T cells, monocytes, complement proteins, acute phase proteins, oxidative injury and related molecular processes. For more information about S uciraslimab, please read the published article on Journal of Neuroinflammation. Link： https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-025-03361-2 Media enquiries Strategic Financial Relations Limited Veron Ng Tel: +852 2864 4831 Email: [email protected] Phoenix Fung Tel: +852 2114 4939 Email: [email protected] Shannon Lei Tel: +852 2114 2881 Email: [email protected] Will Cheng Tel: +852 2864 4894 Email: [email protected]

The release as fetched from its publisher. sinomab.com ↗